Objectives COVID-19 causes lung parenchymal and endothelial damage that lead to hypoxic acute respiratory failure (hARF). The influence of hARF severity on patients’ outcomes is still poorly ...
A PaO2 test measures oxygen pressure in arterial blood to help guide treatment for respiratory issues. This test is part of an arterial blood gas (ABG) test, which also measures other components like ...
Abstract: This paper proposes a novel mathematical model that quantitatively defines the relationships between the arterial oxygen saturation (SaO2), the arterial partial pressure of oxygen (PaO2) and ...
Lungpacer Medical, the award-winning medical device company founded by BPK professor Andy Hoffer in 2009 and spun out from the SFU Neurokinesiology Lab in 2014, achieved a key milestone on December 5, ...
Patients with COPD who travel to high altitudes have an estimated PaO2 decrease of 0.84 kPa with each 1000 meter of altitude gain. High-altitude travel in patients with chronic obstructive pulmonary ...
The following is a summary of “Prognostic value of PaO2/FiO2 ratio in predicting clinical outcomes in COVID-19 patients,” published in the June 2024 issue of Critical Care by Canto-Costal et al.
Chronic obstructive pulmonary disease (COPD) is globally the third leading cause of death, causing 3.23 million deaths in 2019. Most feasible way to measure oxygen saturation is by pulse oximetry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results